James N Topper
CIK 1341382 · last filed 2026-05-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.11B
Companies
17
Total Filings
114
Lifetime Open-Market Net
$281.48M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PHAT | Director | 126,121 | $11.66 | $1.47M | $100.19M | 10 | 2026-05-21 |
| NAMSW | Director | 3,801,000 | $19.38 | $73.66M | $586.2K | 8 | 2025-09-17 |
| MBX | 10%+ Owner | 4,552,774 | $60.06 | $273.44M | $40.00M | 1 | 2024-09-17 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Director | 1,371,450 | $64.97 | $89.10M | $2.00M | 13 | 2024-05-20 |
| HilleVax, Inc. (HLVX) Delisted | 10%+ Owner | 8,544,187 | $2.09 | $17.86M | $641.6K | 1 | 2024-04-08 |
| ANAB | Director | 280,341 | $52.11 | $14.61M | $6.00M | 10 | 2023-01-10 |
| Allena Pharmaceuticals, Inc. (ALNA) Delisted | Director | 1,466,805 | $0.07 | $110.0K | $7.00M | 4 | 2020-11-18 |
| Aptinyx Inc. (APTX) Delisted | Director | 3,195,055 | $0.06 | $194.9K | $2.40M | 7 | 2020-04-02 |
| PASG | 10%+ Owner | 148,862 | $4.57 | $680.3K | $39.60M | 1 | 2020-03-03 |
| MIRM | 10%+ Owner | 3,116,912 | $112.23 | $349.81M | $27.00M | 1 | 2019-07-24 |
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Director | 337,707 | $2.19 | $739.6K | $5.64M | 2 | 2019-01-22 |
| Sierra Oncology, Inc. (SRRA) Delisted | Director | 148,148 | $54.99 | $8.15M | $8.00M | 1 | 2017-02-16 |
| Sierra Oncology, Inc. (DNAI) Delisted | Director | 1,966,195 | — | — | $3.74M | 2 | 2016-06-20 |
| GKOS | 10%+ Owner | 2,603,362 | $151.33 | $393.97M | $0 | 1 | 2015-06-30 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Director | 907,464 | $14.49 | $13.15M | $34.05M | 46 | 2013-06-17 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 7,252 | — | — | $0 | 2 | 2013-06-07 |
| LA JOLLA PHARMACEUTICAL CO (LJPC) Delisted | Director | 84,214 | $6.22 | $523.8K | $4.63M | 4 | 2009-02-26 |
Recent Filings · Page 2 of 12
114 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-28 | NAMSW | Buy (P) | +1,135 | $25.5K | EDGAR |
| 2025-03-06 | NAMSW | Buy (P) | +4,005 | $84.2K | EDGAR |
| 2024-09-17 | MBX | Mixed | +18,211,096 | $40.00M | EDGAR |
| 2024-05-24 | PHAT | Grant (A) | +10,500 | $0 | EDGAR |
| 2024-05-20 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Mixed | −2,829,347 | $0 | EDGAR |
| 2024-04-29 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Mixed | +1,199,981 | -$27 | EDGAR |
| 2024-04-08 | HilleVax, Inc. (HLVX) Delisted | Buy (P) | +44,250 | $641.6K | EDGAR |
| 2024-03-28 | NAMSW | Buy (P) | +8,429 | $181.2K | EDGAR |
| 2024-01-04 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-13 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Exer (X) | +145,251 | $1.85M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.